Prelude Therapeutics Incorporated
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Prelude Therapeutics Incorporated's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-61.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 76% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-20.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 55% of Healthcare companies in United States.
Cash Cushion Ratio
+30%Cash, after subtracting all debt, equals 30% of its market value (net cash).
Higher than 68% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Prelude Therapeutics Incorporated made a loss over the last year. Prelude Therapeutics Incorporated owes $0.29 for every $1 it owns. Prelude Therapeutics Incorporated made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPrelude Therapeutics Incorporated made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.15The share price is 2.15 times Prelude Therapeutics Incorporated's book value per share, lower than 56% of Healthcare companies in United States.
Market cap
$287 MThe total market value of all of Prelude Therapeutics Incorporated's shares at today's price (share price × number of shares), smaller than 52% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$134 MWhat Prelude Therapeutics Incorporated would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.68Net worth divided by the number of shares. The share price of $3.60 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-57.7%Prelude Therapeutics Incorporated lost 57.7% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
Owes vs Owns
0.29×Prelude Therapeutics Incorporated owes $0.29 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Dividend yield
NonePrelude Therapeutics Incorporated does not currently pay a dividend.
Revenue growth
+73%Revenue rose 73% in the year to Dec 2025.
Profit growth
LossPrelude Therapeutics Incorporated made a loss in each of the last two years.
Profit margin
-819.6%Prelude Therapeutics Incorporated lost $820 for every $100 of revenue.
Cash vs debt
Net cashPrelude Therapeutics Incorporated held $85 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Prelude Therapeutics Incorporated: $287 M ÷ $134 M (30 Jun 2026) = 2.1.
What is Prelude Therapeutics Incorporated's return on equity?
Prelude Therapeutics Incorporated lost 57.7% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
How much does Prelude Therapeutics Incorporated owe compared with what it owns?
Prelude Therapeutics Incorporated owes $0.29 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Does Prelude Therapeutics Incorporated pay a dividend?
No. Prelude Therapeutics Incorporated does not currently pay a dividend.
Is Prelude Therapeutics Incorporated's revenue growing?
Revenue rose 73% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.